US005773459A

United States Patent [19]

Tang et al.

[11] **Patent Number: 5,773,459**

[45] **Date of Patent: Jun. 30, 1998**

[54] **UREA- AND THIOUREA-TYPE COMPOUNDS**

[75] Inventors: **Peng Cho Tang**, Moraga; **Gerald McMahon**, Kenwood, both of Calif.

[73] Assignee: **Sugen, Inc.**, Redwood City, Calif.

[21] Appl. No.: **486,816**

[22] Filed: **Jun. 7, 1995**

[51] **Int. Cl.**[6] **A61K 31/38**; C07D 333/10

[52] **U.S. Cl.** **514/445**; 514/326; 514/327; 514/347; 514/371; 514/426; 514/585; 514/596; 514/597; 546/23; 546/208; 546/212; 546/216; 546/306; 548/196; 548/557; 548/559; 549/63

[58] **Field of Search** 514/585, 596, 514/597, 445, 347, 327, 326, 371, 426; 564/26, 48, 49; 546/306, 216, 23, 212, 208; 548/196, 557, 559; 549/63

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,609,619	9/1986	Katoh et al.	430/553
4,623,662	11/1986	DeVries	514/596
4,629,731	12/1986	Lobbestael et al.	514/353
4,966,849	10/1990	Vallee et al.	435/199
5,162,360	11/1992	Creswell et al.	514/371
5,217,999	6/1993	Levitzki et al.	514/613
5,302,606	4/1994	Spada et al.	514/357
5,330,990	7/1994	Hansen	514/299
5,330,992	7/1994	Eissenstat et al.	514/312
5,401,757	3/1995	Backhouse et al.	514/347
5,464,863	11/1995	Nagamine et al.	514/443

FOREIGN PATENT DOCUMENTS

566 266	10/1993	European Pat. Off. .
WO 91/15495	10/1991	WIPO .
WO 92/20642	11/1992	WIPO .
WO 92/21660	12/1992	WIPO .
WO 94/03427	2/1994	WIPO .
WO 94/10202	5/1994	WIPO .
WO 94/14808	7/1994	WIPO .

OTHER PUBLICATIONS

Aaronson, S. A. (1991). Growth factors and cancer, Science 254, 1146–1153.

Arvidsson, A.–K., et al. (1994). Tyr–716 in the platelet–derived growth factor b–receptor kinase insert is involved in GRB2 binding and ras activation. Molecular and Cellular Biology 14, 6715–6726.

Baserga, R. (1995). The insulin–like growth factor I receptor: a key to tumor growth? Cancer Research 55, 249–252.

Bisbee, C. (1995). Scatter factor/hepatocyte growth factor gene deletion leads to death in knockout mice. BioWorld Today 24 Feb. 1995, 2.

Carraway, L. K., et al. (1994). The erbB3 Gene Product Is a Receptor for Heregulin. The Journal of Biological Chemistry 269, 14303–14306.

Carraway, K. L., and Canthley, L.C. (1994). A New Acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling. Cell 78, 5–8.

Claesson–Welsh, L. (1994). Signal transduction by the PDGF receptors. Progress in Growth Factor Research 5, 37–54.

Cullen, K. J., Yee, D., and Rosen, N. (1991). Insulinlike Growth Factors in Humam Malignancy. Cancer Investivation 9, 443–454.

Dati, C., Antoniotti, S., Taverna, D., Perroteau, I., and De Bortoli, M. (1990). Inhibition of c–erB–2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5, 1001–1006.

Decker, T., and Lohmann–Matthes, M.–L., (1988). A quick and simple method for quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. of Imm. Methods 15, 61–69.

de Vries, C., Escobedo, J. A. Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. (1992). The fms–like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989–991.

Dougall, W. C., Qian, X., Peterson, N. C. Miller, M. J. Samanta, A., and Greene, M. I. (1994). The neu–oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9: 2109–2123.

Fendly, B. M. (1990). Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Research 50, 1550–1558.

Ferrara, N., and Henzel, W. J. (1989). Pituitary follicular cells secrete a novel heparin–binding growth factor specific for vascular endothelial cells. Biochemical and Biophysical Research Communications, 161, 851–858.

Fingl, E., and Woodbury, D. M. (1975). The Pharmacological Basis of Therapeutics Chapter I, 1–46.

Floege, J., Eng., E., Young, B. A., and Johnson, R. J. (1993). Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney International 43, S–47—S54.

Folkman, J. (1971). Tumor Angiogenesis: therapeutic implications. The New England Journal of Medicine v. 285,18 Nov. 1971, 1182–1186.

Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82, 4–6.

Folkman, J., and Shing, Y. (1992). Angiogenesis. The Journal of Biological Chemistry 267, 10931–10934.

Fry, M. J., Panayotou, G., Booker G. W., and Waterfield, M. D. (1993). New insignts into protein–tyrosine kinase receptor signaling complexes. Protein Science 2, 1785–1797.

Giordano, S., Di Renzo, M. F., Olivero, M., Mondino, A., Zhen, Z., Medico, E., and Comoglio, P. M. (1992). The c–met/HGF receptor in human tumours. European Journal of Cancer Prevention 1, 45–49.

(List continued on next page.)

Primary Examiner—Shailendra Kumar
Attorney, Agent, or Firm—Lyon & Lyon LLP

[57] **ABSTRACT**

The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.

18 Claims, No Drawings